HealthCare Investors Beware: US Attorney Sues Private Equity Firm ...
The National Law Review-17 minutes ago
In that time frame, TRICARE reimbursed for compounded drugs for ESRD (end stage renal disease) patients on a fee-for-service basis based on the “average wholesale price” for each ingredient of the drug minus a negotiated discount. Effective May 1, 2015, TRICARE imposed a screening process for medical necessity ...
No comments:
Post a Comment